Small Molecules in Cancer Immunotherapy
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (25 June 2024) | Viewed by 2339
Special Issue Editors
Interests: medicinal chemistry; rational drug design; heterocyclic compounds; structure–activity relationships; adenosine receptor ligands; carbonic anhydrase inhibitors; protein kinase CK1 and CK2 inhibitors; ecto-5'-nucleotidase (CD73) inhibitors
Special Issues, Collections and Topics in MDPI journals
Interests: medicinal chemistry; rational drug design; heterocyclic compounds; structure–activity relationships; adenosine receptor ligands; carbonic anhydrase inhibitors; protein kinase CK1 and CK2 inhibitors; ecto-5'-nucleotidase (CD73) inhibitors
Special Issues, Collections and Topics in MDPI journals
Interests: medicinal chemistry; rational drug design; heterocyclic compounds; structure–activity relationships; adenosine receptor ligands; carbonic anhydrase inhibitors; protein kinase CK1 and CK2 inhibitors; ecto-5'-nucleotidase (CD73) inhibitors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer is a multifaceted disease and constitutes a great challenge to society, as it is the leading cause of mortality worldwide. There are different types of cancer that arise in different organs, each requiring specific pharmacological approaches. Cancer immunotherapy, either on its own or in combination with other strategies, represents the new frontier in oncological treatment. Immunotherapy enables the immune system to recognize and target cancer cells. Current cancer immunotherapies are mostly antibody-based, thereby possessing pharmacokinetic limitations such as long half-lives, poor tissue/tumor penetration, and scarce oral bioavailability. Furthermore, therapeutic antibodies may cause severe unwanted adverse effects due to their immunogenic nature. However, small molecules targeting defined pathways and/or cells involved in immunomodulation may overcome the abovementioned disadvantages, thus improving the efficacy of cancer therapy. Specifically, they act at the extracellular or intracellular levels, can be administrated orally, and their shorter half-lives could reduce the risk of systemic toxicity. Hence, the rapid development of small molecules for cancer immunotherapy has been witnessed over recent years.
Authors are invited to submit original articles presenting their research in this field. The proposed topic is in relation to small molecules as immunomodulators for cancer therapy, such as those targeting PD-1/PD-L1, chemokine receptors, Toll-like receptors, A2A/A2B adenosine receptors, and CD39/CD73. Moreover, review articles summarizing knowledge on these topics are also of interest.
Prof. Dr. Daniela Catarzi
Prof. Dr. Vittoria Colotta
Dr. Flavia Varano
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
-
cancer immunotherapy
-
small molecules
-
immunocheckpoints
-
PD-1/PD-L1
-
A2A/A2B adenosine receptors
-
toll-like receptor
-
chemokine receptors
-
CD39/CD73
